Geneuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsy… Read more
Geneuro SA (GNRO) - Net Assets
Latest net assets as of December 2023: €-13.78 Million EUR
Based on the latest financial reports, Geneuro SA (GNRO) has net assets worth €-13.78 Million EUR as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.36 Million) and total liabilities (€20.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-13.78 Million |
| % of Total Assets | -216.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -320.79% |
| Growth Volatility | 30047.56 |
Geneuro SA - Net Assets Trend (2012–2023)
This chart illustrates how Geneuro SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Geneuro SA (2012–2023)
The table below shows the annual net assets of Geneuro SA from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €-13.78 Million | -1074.88% |
| 2022-12-31 | €1.41 Million | -70.10% |
| 2021-12-31 | €4.73 Million | -13.11% |
| 2020-12-31 | €5.44 Million | +202.52% |
| 2019-12-31 | €-5.31 Million | -95624.51% |
| 2018-12-31 | €5.55K | -57.46% |
| 2017-12-31 | €13.06K | -30.06% |
| 2016-12-31 | €18.67K | +1002.01% |
| 2015-12-31 | €1.69K | -99.97% |
| 2014-12-31 | €6.24 Million | +130.38% |
| 2013-12-31 | €2.71 Million | +4433.76% |
| 2012-12-31 | €-62.50K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Geneuro SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4175760000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €1.10 Million | % |
| Other Comprehensive Income | €42.06 Million | % |
| Other Components | €33.60K | % |
| Total Equity | €-13.78 Million | 100.00% |
Geneuro SA Competitors by Market Cap
The table below lists competitors of Geneuro SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
$868.70K |
|
China Teletech Holding Inc
PINK:CNCT
|
$868.80K |
|
JM SMUCKER
MU:JM2
|
$869.15K |
|
GENETIC ANALYSIS NK -60
F:8V8
|
$869.15K |
|
CHARLES SCHWAB
BE:SWG
|
$868.55K |
|
Network Media Group Inc
OTCQB:NETWF
|
$867.68K |
|
Standard Life PLC
LSE:SDLF
|
$866.93K |
|
WisdomTree US Treasuries 10Y 3x Daily Short
XETRA:TY3S
|
$866.67K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Geneuro SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,413,300 to -13,778,000, a change of -15,191,300 (-1074.9%).
- Net loss of 14,757,000 reduced equity.
- Other comprehensive income decreased equity by 730,100.
- Other factors increased equity by 295,800.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-14.76 Million | -107.11% |
| Other Comprehensive Income | €-730.10K | -5.3% |
| Other Changes | €295.80K | +2.15% |
| Total Change | €- | -1074.88% |
Book Value vs Market Value Analysis
This analysis compares Geneuro SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | €0.00 | €0.03 | x |
| 2013-12-31 | €0.22 | €0.03 | x |
| 2014-12-31 | €0.52 | €0.03 | x |
| 2015-12-31 | €0.14 | €0.03 | x |
| 2016-12-31 | €1.35 | €0.03 | x |
| 2017-12-31 | €0.89 | €0.03 | x |
| 2018-12-31 | €0.38 | €0.03 | x |
| 2019-12-31 | €-0.36 | €0.03 | x |
| 2020-12-31 | €0.28 | €0.03 | x |
| 2021-12-31 | €0.22 | €0.03 | x |
| 2022-12-31 | €0.06 | €0.03 | x |
| 2023-12-31 | €-0.55 | €0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Geneuro SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-150.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | €-3.51 Million |
| 2013 | -129.17% | -16581.99% | 0.01x | 1.55x | €-3.77 Million |
| 2014 | 28.47% | 24.32% | 0.81x | 1.45x | €1.15 Million |
| 2015 | -264.83% | -176.71% | 0.12x | 12.25x | €-4.66K |
| 2016 | -75.55% | -238.33% | 0.16x | 2.02x | €-15.97K |
| 2017 | -44.71% | -39.05% | 0.49x | 2.33x | €-7.14K |
| 2018 | -149.92% | -111.59% | 0.53x | 2.53x | €-8.88K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | €-8.93 Million |
| 2020 | -162.52% | 0.00% | 0.00x | 1.89x | €-9.51 Million |
| 2021 | -144.24% | 0.00% | 0.00x | 2.63x | €-7.29 Million |
| 2022 | -863.21% | 0.00% | 0.00x | 8.08x | €-12.34 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-13.38 Million |
Industry Comparison
This section compares Geneuro SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Geneuro SA (GNRO) | €-13.78 Million | 0.00% | N/A | $868.63K |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |